SlideNewsroom Press Releases In the News Media Inquiries Videos Press Releases Exciting things are happening at Aulos™ Bioscience. Here is the latest news about our company and pipeline. May 25, 2023 Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells ... February 1, 2023 First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors ... November 10, 2022 Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting ... October 31, 2022 Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors ... October 11, 2022 Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting ... May 26, 2022 Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting ... May 5, 2022 Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors ... April 27, 2022 Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting ... March 21, 2022 Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors ... February 23, 2022 Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007 ... Prev1234Next
